FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports

June 30, 2026 - 21:39

Internal documents from the U.S. Food and Drug Administration are casting doubt on the safety and effectiveness of peptides, the increasingly popular molecules that have gained a vocal supporter in Robert F. Kennedy Jr. The documents, which review existing research on the compounds, highlight a troubling lack of solid evidence for both their efficacy and their safety profile.

Peptides, short chains of amino acids, have exploded in popularity in recent years, promoted for a wide range of uses from anti-aging and muscle building to improving skin health and cognitive function. They are often sold online and in clinics without the rigorous testing required for traditional pharmaceuticals. Despite this surge in consumer interest, the FDA's internal review suggests the science has not kept pace with the hype.

The agency's concerns come at a critical time. Later this month, an FDA advisory panel is scheduled to meet and consider proposals that could significantly ease public access to these molecules. The panel will weigh whether to allow broader marketing and distribution of certain peptide products without the standard pre-market approval process. The outcome of this meeting could reshape the regulatory landscape for a multi-billion dollar industry that currently operates in a gray area between supplements and drugs.

Supporters, including Kennedy who has publicly advocated for alternative and less regulated health approaches, argue that peptides offer a natural and effective way to support the body's own healing processes. They contend that excessive regulation stifles innovation and limits patient choice. However, the FDA's internal findings suggest that many of these claims are not backed by reliable clinical trials, and that the long-term risks of widespread use remain unknown. The documents specifically note a lack of data on potential side effects, drug interactions, and the consequences of chronic use. The upcoming panel decision will be closely watched by both the wellness industry and public health advocates.